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One of the major goals of asthma therapy is to maintain asthma control and prevent acute exacerbations.
Long-acting bronchodilators are regularly used for the treatment of asthma patients and in clinical
studies the anti-cholinergic tiotropium has recently been shown to reduce exacerbations in patients with
asthma. So far it is unclear how tiotropium exerts this effect. For this purpose, we designed an allergen-
driven rechallenge model of allergic airway inflammation in mice, to assess the effectiveness of tio-
tropium and the long-acting b-2 adrenoceptor agonist olodaterol on allergen-induced exacerbations of
airway disease.
Female C57BL/6J mice were sensitized intranasally (i.n.) with 1 mg of house dust mite (HDM) extract
followed by a challenge regime (5 consecutive days 10 mg HDM extract i.n.) after one week. Mice were
exposed to a secondary challenge five weeks after sensitization and were treated i.n. with different
concentrations of tiotropium or olodaterol (1, 10 and 100 mg/kg) or a combination thereof (10 mg/kg each)
prior to and during the secondary challenge period. Three days after the last challenge, bronchoalveolar
lavage (BAL) fluid and lung tissue were collected for flow cytometry and histologic analysis, respectively.
Secondary challenge with HDM extract strongly induced allergic airway disease reflected by inflam-
matory cell infiltration and goblet cell metaplasia. Treatment with tiotropium, but not with olodaterol
reduced tissue inflammation and goblet cell metaplasia in a dose-dependent manner. The combination of
tiotropium and olodaterol was more effective in significantly reducing tissue inflammation compared to
tiotropium treatment alone, and also led to a decrease in BAL cell counts.
These data suggest that in a model of relapsing allergic airway disease tiotropium directly prevents
exacerbations by reducing inflammation and mucus production in the airways. In addition, the combi-
nation of tiotropium and olodaterol exerts synergistic effects.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Asthma is a chronic respiratory disease most commonly caused
by hypersensitivity to a variety of allergens and is one of the leading
causes of chronic disease worldwide [1]. The disease pathogenesisumin; BAL, bronchoalveolar lavage
the International Conference of the
P, Taube C. Tiotropium inhibits air
spir Crit Care Med 191 (2015) A42
gy, Leiden University Medical Cent
-Schuster).
Ltd. This is an open access article uis characterized by complex airway inflammatory and remodeling
processes that lead to airway hyperresponsiveness and various
degrees of reversible airflow limitation. Current therapies prefer-
entially consist of a combination of inhaled corticosteroids and
inhaled long-acting b-2 adrenoceptor agonists (LABA) and are; LABA, long-acting b-2 adrenoceptor agonist.
American Thoracic Society 2015 and published as a conference abstract: de Kleijn S,
way inflammation and goblet cell metaplasia in a house dust mite (HDM)-induced
72.
er, Albinusdreef 2, 2333, ZA Leiden, The Netherlands.
nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
G. John-Schuster et al. / Pulmonary Pharmacology & Therapeutics 45 (2017) 210e217 211beneficial in controlling symptoms and airway inflammation, but
have little effect on airway remodeling. However, the majority of
asthmamorbidity occurs in patients suffering from a severe form of
the disease (up to 10% of all asthmatics) with recurring symptoms
and exacerbations that are poorly controlled despite the use of
standard combination therapy [2].
Recent clinical studies have focused on the option of adding a
second long-acting bronchodilator, the anticholinergic agent tio-
tropium that has been used in the (maintenance and exacerbation)
treatment of chronic obstructive pulmonary disease (COPD) for the
past years [3e5]. Tiotropium is a muscarinic receptor antagonist
that is kinetically selective for M3 receptors [6]. Muscarinic re-
ceptor signaling in the airways is primarily induced via the para-
sympathetic neurotransmitter acetylcholine released by both
neuronal and non-neuronal cells including lung structural and in-
flammatory cells [7]. Signaling induces bronchoconstriction and
mucus production by acting on smooth muscles and mucus-
secreting cells in the central airways [8e11]. Blocking the recep-
tor using therapeutic muscarinic receptor antagonists results in
smooth muscle relaxation and reduced mucus production [12].
Besides its function as a bronchodilator, tiotropium has been
demonstrated to reduce signs of allergen-induced airway inflam-
mation in animal models [13e15], and interestingly also in com-
binationwith a novel LABA, olodaterol [16]. However, most of these
studies were performed with allergens irrelevant to the human
situation and so far not in secondary challenge models, in which
airway inflammation has been established. Therefore, the aim of
the current study was to determine the effect of treatment with
tiotropium or olodaterol on allergen-induced exacerbation of
airway inflammation and remodeling. To achieve this, a rechallenge
model of allergic airway inflammation in mice mimicking allergen-
induced exacerbations of the disease was utilized. In addition, a
potential synergistic effect of a combination treatment of tio-
tropium and olodaterol was explored in this model.2. Material and methods
2.1. Animals and maintenance
8-10 weeks old pathogen-free female C57BL/6J mice (Charles
River, 's-Hertogenbosch, The Netherlands) were housed in rooms
maintained at constant temperature and humidity with a 12-h light
cycle. Animals were allowed food and water ad libitum.
All animal procedures were approved by the local animal ethics
committee of the Leiden UniversityMedical Center (license number
13185, Dierexperimentencommissie Academisch Ziekenhuis Lei-
den) and were conducted under strict governmental and interna-
tional guidelines in accordance with EU Directive 2010/63/EU.Fig. 1. Rechallenge model of allergic airway inflammation. Mice were sensitized by intra
50 ml PBS on day 0 (week 1) and challenged intranasally with 10 mg HDM extract in 50 ml PBS
rechallenged intranasally with 10 mg HDM extract once daily on days 35e39 (week 6). Pri
administration of 1, 10 and 100 mg/kg bodyweight (BW) tiotropium (Boehringer Ingelheim; d
thereof (both compounds at 10 mg/kg each) starting on day 34, 24 h before the first rechal2.2. Treatment protocol
Mice were sensitized by intranasal administration of 1 mg house
dust mite extract (HDM; Greer, Lenoir, NC, USA) in 50 ml PBS on day
0 (week 1) and challenged intranasally with 10 mg HDM extract in
50 ml PBS once daily on days 7e11 (week 2). After a recovery period
of three weeks, animals were rechallenged intranasally with 10 mg
HDM extract once daily on days 35e39 (week 6). Prior to and
during the second allergen challenge period, animals were treated
daily by intranasal administration of 1, 10 and 100 mg/kg body-
weight (BW) tiotropium (Boehringer Ingelheim; dissolved in PBS),
olodaterol (Boehringer Ingelheim; dissolved in PBS) or a combi-
nation thereof (both compounds at 10 mg/kg each) starting on day
34, 24 h before the first rechallenge and on days 35e39, 1 h before
the challenge. Intranasal administration was performed under
isoflurane anesthesia (3%, 0.6 L/min). Control animals received 50 ml
PBS intranasally during sensitization, challenge and rechallenge.
For a detailed protocol outline, see Fig. 1.
Three days after the last challenge, mice were euthanized with
sodium pentobarbital and tracheostomized. All animals were lav-
aged, the left lung was removed for flow cytometry analysis, and
the right lung was fixed in paraformaldehyde (PFA; see below).
2.3. Bronchoalveolar lavage (BAL) and lung single cell suspension
BAL fluid and lung single cell suspensions were obtained to
determine lung inflammatory cell recruitment. BAL was performed
by instilling the lungs with 3  1 ml aliquots of sterile PBS (Braun).
Afterwards, cells were spun down at 400 g and resuspended in 0.5%
(w/v) BSA (Sigma)/2 mM EDTA (Invitrogen) FACS buffer. Total cell
counts were determined in a hemocytometer. Remaining cells were
subjected to flow cytometry analysis (see below).
For single-cell suspensions of whole lung tissue, lungs were
perfused with sterile PBS via the right ventricle to clear leukocytes
and erythrocytes from the pulmonary circulation. Lung homoge-
nization was performed via enzymatic digestion and mechanical
dissociation steps using collagenase (1 mg/ml; Calbiochem)/DNase
(20 U/ml; Sigma) and 70 mmcell strainers (Corning) followed by red
blood cell lysis. Single-cell suspensions were subjected to flow
cytometry analysis (see below).
2.4. Flow cytometry
For flow cytometry, cells were stained with live/dead stain Aqua
(Invitrogen) and fixed in 1.9% w/v formaldehyde (Merck). The
following antibodies were used to distinguish different inflamma-
tory cell populations (neutrophils, macrophages, eosinophils, DCs,
B and T cells) in the BAL fluid: Ly-6G/Ly-6C (Gr-1)-FITC (RB6-8C5,nasal administration of 1 mg house dust mite extract (HDM; Greer, Lenoir, NC, USA) in
once daily on days 7e11 (week 2). After a recovery period of three weeks, animals were
or to and during the second allergen period, animals were treated daily by intranasal
issolved in PBS), olodaterol (Boehringer Ingelheim; dissolved in PBS) or a combination
lenge and on days 35e39, 1 h before the challenge.
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PerCP-eFluor710 (17A2, eBioscience), CD11b-PE-Cy7 (M1/70, eBio-
science), MHCII (I-A/I-E)-APC (M5/114.15.2, eBioscience), CD45R
(B220)-APC-eFluor780 (RA3-6B2, eBioscience), and CD11c-V450
(HL3, BD Biosciences). Cells were measured on a FACSCanto II
flow cytometer (BD Biosciences, San Jose, CA) and analysis was
performed using FlowJo (v7.6.5) software (Tree Star, Ashland, OR).
Briefly, single, alive cells were separated into lymphocytes and non-
lymphocytes based on FSC/SSC characteristics of the different
populations. In the non-lymphocyte gate, eosinophilic granulocytes
were identified as CD11cSiglec-Fþ.
2.5. Histology
Lung tissue was fixed by intratracheal instillation of PBS buff-
ered 3.9% w/v paraformaldehyde (PFA) and embedded into paraffin
for hematoxylin-eosin (H&E) or periodic acid-Schiff (PAS) staining
according to standard protocols. For determination of lung histo-
pathology, tissue sections were examined in blinded fashion on a
BX40 Olympus microscope. Peribronchial inflammationwas scored
on a scale from 0 to 4. PAS-positive goblet cells were quantified per
1 mm of basement membrane using ImageJ software.
2.6. Statistical analysis
Results are given as mean values ± SEM. One-way ANOVA
following Dunnett post test was used for all studies. Analyses were
conducted using GraphPad Prism 6 software (GraphPad Software,
La Jolla, USA), and differences with p < 0.05 were considered sta-
tistically significant. Synergy between the effects of tiotropium and
olodaterol was calculated by comparing the calculated sum of the
effects of the individual drugs to the measured effect of the com-
bination treatment using a Student's t-test, with p < 0.05 indicating
a statistically significant difference showing synergistic activity.
3. Results
3.1. Tiotropium reduces allergic airway inflammation and
remodeling after HDM rechallenge in a dose dependent manner
Tiotropium has been demonstrated to reduce exacerbations in
patients with asthma [17]. To determine the effect of tiotropium
monotherapy on relapsing allergic airway inflammation, mice were
challenged with HDM extract in 2 periods of 5 days with three
weeks recovery in between challenges (see Fig. 1). Prior to and
during the second challenge, mice were treated with 1, 10 and
100 mg/kg BW of tiotropium. Treatment had no effect on the
number of total cells and eosinophils in BAL fluid (Fig. 2A). How-
ever, when analyzing lung tissue, treatment with tiotropium
resulted in a dose dependent decrease of airway inflammation and
PAS-positive cells, and this reduction was statistically significant
compared to the non-treated animals at the highest dose of tio-
tropium (Fig. 2BeE).
3.2. Olodaterol monotherapy does not reduce allergic airway
inflammation after HDM rechallenge
Besides its bronchodilatory function, olodaterol has also been
described to have anti-inflammatory properties [18]. To determine
whether olodaterol is able to inhibit allergen-induced exacerba-
tions, mice were treated prior to and during the second challenge
with different doses of olodaterol. Treatment with olodaterol had
no effect on airway inflammation in both BAL and lung tissue
(Fig. 3AeC). In addition, treatment with olodaterol did not affect
the number of PAS-positive cells in this model (Fig. 3DeE).3.3. A combination of tiotropium and olodaterol has a synergistic
effect on airway inflammation in the HDM rechallenge model
To assess if tiotropium and olodaterol have synergistic effects
when used in combination, micewere treatedwith an intermediate
dose of tiotropium (10 mg/kg BW) in combination with an inter-
mediate dose of olodaterol (10 mg/kg BW). Both compounds did not
reduce airway inflammation with these doses when applied in
monotherapy (Figs. 2 and 3). In contrast, treatment with a combi-
nation of olodaterol and tiotropium significantly and synergistically
reduced total cell and eosinophil counts in BAL fluid (Fig. 4A). In
addition, a significant reduction in tissue inflammation following
combination treatment was detectable and was found to be
resulting from an additive effect rather than a synergistic effect of
the combination (Fig. 4BeC). However, goblet cell metaplasia was
not significantly reduced in tiotropium/olodaterol-treated mice
(Fig. 4DeE).
4. Discussion
Our study aimed at investigating the effects of a long-acting
anti-cholinergic and a long-acting beta-2-agonist on allergen
induced asthma exacerbations in an allergen-induced rechallenge
model of allergic airway inflammation. In the present study we
show that treatment with the anticholinergic tiotropium inhibits
tissue inflammation and goblet cell metaplasia induced by rechal-
lenge with allergen, in contrast to treatment with the long-acting
beta-2-agonists olodaterol. Interestingly, when used in combina-
tion, tiotropium and olodaterol showed a synergistic effect on the
reduction of airway inflammation, specifically BAL total cell and
eosinophil numbers.
Tiotropium has been the focus of many clinical studies due to its
successful use in maintenance and exacerbation treatment of COPD
[3e5]. In comparative asthma studies with adrenergic agents, tio-
tropium was found to be as effective as (or non-inferior to) sal-
meterol in improving symptoms and lung function when added to
an inhaled glucocorticoid in patients with inadequately controlled
asthma [19e21]. Furthermore, the addition of once-daily tio-
tropium to standard asthma combination treatment not only
improved lung function [17,22], but also significantly increased the
time to the first severe exacerbation, with an overall risk reduction
of 21% [17]. Based on these results, tiotropium was recently
approved as add-on treatment in long-term maintenance therapy
of asthma [1,23,24]. However, it is currently unclear how tio-
tropium exerts its effects on asthma exacerbations.
In the present study we provide additional evidence that tio-
tropium has anti-inflammatory effects in allergen-induced exac-
erbations of airway disease. Tiotropium has been shown to reduce
allergic airway inflammation in different models of allergic airway
disease. Indeed, in guinea pigs tiotropiumwas similarly effective as
the corticosteroid budesonide in inhibiting or reducing several
aspects of airway inflammation and remodeling following chal-
lenges with ovalbumin (OVA) [25,26]. Similar results were found in
different murine models of OVA-induced airway inflammation.
Again, treatment with tiotropium significantly reduced airway
inflammation and remodeling [13,14]. Buels et al. further identified
that non-bronchodilating anti-inflammatory mechanisms of tio-
tropium were responsible for reducing airway hyperreactivity in a
guinea pig OVA model of allergic asthma via inhibition of eosino-
phil accumulation in the lungs [27]. Treatment effects on inflam-
mation and mucus hypersecretion in mice were also comparable to
the corticosteroid dexamethasone, both during initiation and
relapse of the disease induced by allergen rechallenge 90 days after
the last challenge [15].
However, tiotropium effects have mainly been studied using
Fig. 2. A high dose of tiotropium treatment inhibits airway inflammation and goblet cell metaplasia. Mice were treated with 3 different doses of tiotropium (1, 10 and 100 mg/
kg BW) prior to and during the second allergen challenge period. A Total inflammatory cells in BAL fluid were determined in a hemocytometer; absolute number of eosinophils were
measured using FACS analysis by gating on CD11cSiglec-Fþ cells; B representative micrographs of H&E-stained lung tissue sections from naïve, HDM allergic and HDM allergic mice
treated with tiotropium, scale bar 200 mm; C quantification of lung tissue inflammation; D representative micrographs of PAS-stained lung tissue sections from naïve, HDM allergic
and HDM allergic mice treated with tiotropium, scale bar 50 mm; E number of PAS-positive cells per mm of basal membrane. Graphs show mean ± SEM; n ¼ 12 mice; *p < 0.05.
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proaches, such as starting treatment before the first allergen
exposure. In the present study we utilized the human relevant
allergen HDM [28]. In addition we made use of a secondary expo-
sure in which mice had already developed allergic airway inflam-
mation until they are challenged again, mimicking allergen-
induced exacerbation of airway disease. We observed that tio-
tropium inhibited airway inflammation and goblet cell metaplasia
after HDM rechallenge, whereas BAL cell counts were not affected,
potentially due to ongoing and increased clearance of inflammatory
cells via the airway lumen.
The anti-inflammatory effects of tiotropium are thought to be
directly related to inhibition of acetylcholine-mediated production
of pro-inflammatory factors and the subsequent accumulation of
inflammatory cells in the lung in response to allergens. Both in-
flammatory and epithelial cells have been described to induce pro-
inflammatory responses via acetylcholine andmuscarinic receptorsexpressed throughout the lung [29e31], and tiotropiumwas able to
inhibit these responses. While these results point towards an in-
hibition of remodeling as a consequence of reduced inflammation,
it might also be caused by direct inhibitory effects on broncho-
constriction. This is supported by a recent study demonstrating that
repeated methacholine challenge in patients with asthma induced
airway remodeling, without an effect on inflammation [32]. Simi-
larly, knockout of the M3 receptor in mice reduced allergen-
induced parameters of airway remodeling, such as goblet cell
metaplasia, smooth muscle thickening and collagen deposition
[33], but did not affect inflammation including eosinophil numbers
and Th2 cytokine levels. Furthermore, tiotropium has been shown
to directly inhibit and reverse IL-13-induced goblet cell metaplasia
and mucus (MUC5AC) production in primary human airway
epithelial cells (indicating a direct effect of non-neuronal acetyl-
choline in this process) [34]. This might also help to explain the
significant effects on remodeling observed in our study.
Fig. 3. Olodaterol does not inhibit airway inflammation and goblet cell metaplasia. Mice were treated with 3 different doses of olodaterol (1, 10 and 100 mg/kg BW) prior to and
during the second allergen challenge period. A Total inflammatory cells in the BAL fluid were determined in a hemocytometer; absolute number of eosinophils were measured using
FACS analysis; B representative micrographs of H&E-stained lung tissue sections from naïve, HDM allergic and HDM allergic mice treated with olodaterol, scale bar 200 mm; C
quantification of lung tissue inflammation; D representative micrographs of PAS-stained lung tissue sections from naïve, HDM allergic and HDM allergic mice treated with olo-
daterol, scale bar 50 mm; E number of PAS-positive cells per mm of basal membrane. Graphs show mean ± SEM; n ¼ 12 mice; *p < 0.05.
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more significant treatment effect on airway inflammation com-
bined with a reduction in BAL cell counts when a lower dose of
tiotropium (10 mg/kg BW) was combined with olodaterol (10 mg/kg
BW), a novel and highly selective LABA approved for long-term,
once-daily maintenance bronchodilator treatment in COPD pa-
tients [35]. Olodaterol exerts its pharmacological effects by binding
and activating beta-2 adrenoceptors in the airways, which stimu-
lates intracellular adenyl cyclase, an enzyme that mediates the
synthesis of cyclic adenosine monophosphate (cAMP). Elevated
levels of cAMP induce bronchodilation by relaxation of airway
smooth muscle cells [35]. Beneficial therapeutic effects of tio-
tropium/olodaterol combination treatment have especially been
described for COPD [36,37]. In (moderate to very severe) COPD
patients, the combination treatment improved lung function and
health-related quality of life compared to monotherapy with eithertiotropium or olodaterol alone [38e40]. The benefits are related to
the maximized bronchodilating effect mediated by b-2
adrenoceptor-dependent intracellular cAMP increase combined
with the competitive antagonism of M3 receptors [36]. Thus, a
combination therapy of tiotropium/olodaterol (Stiolto Respimat)
has recently been approved for the maintenance of COPD [41,42].
In a guinea pig model of allergic asthma (OVA), tiotropium
synergistically enhanced the bronchoprotective effect of olodaterol
[16]. However, Smit et al. did not observe any treatment effect on
inflammatory cell infiltration in the airways, which is in contrast to
our results obtained after combination treatment. Interestingly, in
pulmonary fibroblasts from asthmatic and non-asthmatic subjects
a combination of tiotropium and olodaterol restored intracellular
cAMP levels beyond levels induced by olodaterol alone and thereby
significantly reduced IL-1b-induced IL-8 and IL-6 release compared
to tiotropium or olodaterol treatment alone [18]. However, Costa
Fig. 4. A combination of tiotropium and olodaterol synergistically reduces allergic airway inflammation after allergen rechallenge. Mice were treated with a combination of
tiotropium (10 mg/kg BW) and olodaterol (10 mg/kg BW) prior to and during the second allergen challenge period with HDM. A Total inflammatory cells in the BAL fluid were
determined in a hemocytometer; absolute number of eosinophils were measured using FACS analysis; B representative micrographs of H&E-stained lung tissue sections from naïve,
HDM allergic and HDM allergic mice treated with tiotropium/olodaterol, scale bar 200 mm; C quantification of lung tissue inflammation; D representative micrographs of PAS-
stained lung tissue sections from naïve, HDM allergic and HDM allergic mice treated with tiotropium/olodaterol, scale bar 50 mm; E number of PAS-positive cells per mm of
basal membrane. Graphs show mean ± SEM; n ¼ 12 mice; *p < 0.05.
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already provided a strong negative signal for fibroblast inflamma-
tory responses including the production and release of pro-
inflammatory cytokines and chemokines. This is in contrast to the
generally accepted concept that LABAs are devoid of any clinically
meaningful anti-inflammatory activity in vivo [43,44], which we
also confirm in our rechallenge model with olodaterol treatment
alone.
Nevertheless, the described mechanism could also explain the
findings obtained in our study, where a lower dose of tiotropium in
combination with olodaterol inhibited inflammation but not
remodeling. In line with this, Buels et al. showed that OVA-induced
airway hyperreactivity in guinea-pigs was prevented by a lower
dose of tiotropium that was unable to inhibit vagally-inducedbronchoconstriction, most likely related to a potential anti-
inflammatory mechanism exerted by the lower dose of tio-
tropium as shown by inhibition of eosinophil accumulation in the
lungs and around nerves [27]. These data suggest that anti-
inflammatory actions of tiotropium are apparent at lower doses
than are required for bronchodilation and might thus precede the
effects on remodeling and bronchoconstriction. This is further
supported by the above-mentioned study by Smit et al. who found
that tiotropium and olodaterol treatment at relatively high con-
centrations inhibited OVA-induced bronchoconstriction but had no
effect on inflammatory cell infiltration in the airways [16].
In summary, the present data show an effect of tiotropium
treatment on the development of allergic airway inflammation in a
murine model of allergen rechallenge using the human relevant
G. John-Schuster et al. / Pulmonary Pharmacology & Therapeutics 45 (2017) 210e217216allergen HDM. Treatment with olodaterol did not inhibit the
development of airway inflammation, however in combination
with tiotropium it synergistically reduced recurrent allergic airway
inflammation induced by allergen rechallenge. Tiotropium is
increasingly utilized in human asthma treatment and has been
associated with a reduction of acute exacerbations in asthma pa-
tients [45]. Whether treatment with tiotropium alone and in
combination with olodaterol is also effective in reducing chronic
inflammation needs to be assessed in further studies both in animal
models of the disease and in patients with asthma.
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